CA-ESRI
24.6.2021 14:02:10 CEST | Business Wire | Press release
Esri , the global leader in location intelligence, today announced it is releasing for the first time ever a new high-resolution, 2020 global land cover map as part of the company’s Living Atlas . The map was built using European Space Agency (ESA) Sentinel-2 satellite imagery, and developed using a new machine learning workflow teaming with new Esri Silver Partner Impact Observatory , as well as long-time partner Microsoft.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005176/en/
The new map will be updated annually supporting change detection and highlighting planetary land changes, especially related to the effects of human activity. A consistent map of land cover for the entire world based on the most current satellite information, the 2020 Global Land Cover Map can be combined with other data layers for green infrastructure, sustainability projects, and other conservation efforts that require a holistic picture of both the human and natural footprint on the planet. Later this year, Esri and Impact Observatory will make this new land cover model available to support on-demand land cover classification, allowing the GIS community to create maps for project areas as often as every week.
"This is a critical year for climate action," said Jack Dangermond, Esri founder and president. "With the UN Climate Change Conference of the Parties (COP26) bringing international parties together to address a set of common goals, we are happy to do our part in making this map available to users that are working towards the health of our planet."
Users will also be able to manipulate the map in association with other GIS layers such as terrain, hydrology, and more, all available in ArcGIS Living Atlas of the World, the foremost collection of geographic information from around the globe, including maps, apps, and data layers. Through the visualizations being released, planners worldwide will better understand the geography around them to make more informed decisions—enabling them to gain insight into locations with distinctive land cover, as well as human activity affecting them.
High-resolution, open, accurate, comparable, and timely land cover maps are critical for decision-makers in many industry sectors and developing nations. These maps improve understanding of important topics such as food security, land use planning, hydrology modeling, and resource management planning. In addition, national government resource agencies use land cover as a basis for understanding trends in natural capital, which helps define land planning priorities and is the basis of budget allocations.
Impact Observatory, contracted by Esri, developed a deep learning AI land classification model using a massive training dataset of billions of human-labeled image pixels, and applied this model to the Sentinel-2 2020 scene collection, processing over 400,000 Earth observations to produce the map. The unique machine learning approach used to create this global map will soon be available on demand, supporting land managers who need to monitor change in a specific area of interest, looking at annual change and seasonal differences in land cover.
"Global efforts are urging world leaders to set and achieve ambitious conservation targets," said Steve Brumby, Impact Observatory co-founder and CEO. "With support from the geospatial experts at Esri, and access to incredible compute resources at Microsoft, we were able to build in record time a land cover map that provides leaders in governments, NGOs, and across industries with a novel, timely view of the planet, and a new AI-powered capability for actionable, science-based insights on demand. In doing so, Impact Observatory hopes to contribute towards the global conservation effort."
Esri is releasing this valuable resource under a Creative Commons license to encourage broad adoption and ensure equitable access for planners creating a more sustainable planet. This content will be made available in ArcGIS Online as a map service and be freely available for use by its 10 million users. It will also be available for download and viewing. To explore the new 2020 Global Land Cover Map, visit livingatlas.arcgis.com/landcover .
About Impact Observatory
Impact Observatory is a mission-driven technology company bringing artificial intelligence (AI) powered algorithms and on-demand data to sustainability and environmental risk analysis for governments, non-profit organizations, companies, and markets. Founded in 2020 in Washington, DC, Impact Observatory’s goal is to empower global decision-makers to be planetary superheroes, with the timely, actionable science-based insights they need to succeed. Visit us at impactobservatory.com .
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .
Copyright © 2021 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005176/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
